Interferon-ribavirin therapy for chronic hepatitis C: efficacy in Saudi patients.
Hepatitis C affects 2% of Saudi population. Previous local trials showed low response to interferon monotherapy for six-months. To evaluate biochemical and virological response of interferon-ribavirin combination on naive Saudi patients infected with HCV. A prospective single armed study was conducted at Riyadh Armed Forces Hospital from July 1999 to July 2002 for fifty patients who have hepatitis C virus (HCV-PCR) positive and chronic hepatitis on liver biopsy were started on the combination therapy for one-year. All had HCV-PCR at the end of therapy and at six months follow-up. Thirty-one patients (62%) normalized their ALT levels, and 25 patients (50%) became HCV-PCR negative achieving end-of-treatment response (ETR). The sustained virological response (SR) was achieved in 19 patients (38%) at six months follow-up after stopping the treatment. Side effects were mainly flu like syndrome in 36 patients (72%). Combination therapy of interferon alfa-2b plus ribavirin is an effective treatment modality for HCV infected Saudi patients, with tolerable side effects. Our virological response rates are compatible with international published literatures.